VistaGen Therapeutics
Tracked across 9 events · 130 articles · First seen Jan 28, 2026 · Last active Mar 13, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
VistaGen Therapeutics is facing a class action securities lawsuit due to alleged securities fraud. The lawsuit stems from the failure of its Phase 3 PALISADE-3 trial for fasedienol, which led to a significant drop in its stock price.
Jan 29, 2026 · 7 articles
Regulatory
VistaGen Therapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its Phase 3 PALISADE-3 trial of fasedienol. This lawsuit could lead to significant financial penalties and reputational damage for the company.
Jan 29, 2026 · 7 articles
Business
VistaGen Therapeutics is facing a class action lawsuit for allegedly making false and misleading statements regarding the success of its fasedienol drug candidate's Phase 3 PALISADE-2 trial. This has led to investor losses and a negative impact on the company's reputation and stock price.
Jan 28, 2026 · 43 articles
Business
VistaGen Therapeutics is facing a class action lawsuit due to the failure of its PALISADE-3 Phase 3 study for intranasal fasedienol, which led to an 80.25% drop in its stock price. The lawsuit alleges securities fraud and other unlawful business practices.
Jan 30, 2026 · 21 articles
Business
VistaGen Therapeutics is facing a class action lawsuit due to allegedly misleading statements regarding its Phase 3 PALISADE-3 trial for fasedienol. The failure of the trial's primary endpoint led to an over 80% decline in its stock price.
Jan 28, 2026 · 7 articles
+ 4 more events
View on Dashboard
NEWSDESK
Track VistaGen Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard